719 results about "RNA - Ribonucleic acid" patented technology

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as JAK. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as ETS2. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to overexpression of the target biomolecule.

Disclosed are compositions comprising a nucleic acid molecule. The nucleic acid molecule may encode an exonic sequence or portion thereof of a target ribonucleic acid (RNA) sequence. The nucleic acid molecule may further encode one or more stabilization domains. The one or more stabilization domains may be configured to reduce a cellular nuclease activity compared to a nucleic acid molecule that does not comprise the one or more stabilization domains.

The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

The disclosure relates to double-stranded ribonucleic acid (dsRNA) targeting an INHBE gene, and methods of using the dsRNA to inhibit expression of INHBE.

The invention relates to adaptors for sequencing nucleic acids. The adaptors may be used to generate single stranded constructs of nucleic acid for sequencing purposes. Such constructs may contain both strands from a double stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) template. The invention also relates to the constructs generated using the adaptors, methods of making the adaptors and constructs, as well as methods of sequencing double stranded nucleic acids.

The invention provides a correlation prediction model training method, a correlation prediction method and a correlation prediction system, and the method comprises the steps: obtaining a plurality of training samples which are obtained through the construction of first sample multi-source features and second sample multi-source features with correlation labels, the first sample multi-source feature is a multi-source feature corresponding to sample micro ribonucleic acid, and the second sample multi-source feature is a multi-source feature corresponding to a sample physiological state type; inputting the plurality of training samples into a preset model, and training the preset model based on vertex vector representation output by a fusion feature layer of the preset model to obtain a trained association prediction model; and the fusion feature layer is used for carrying out fusion processing on the global attention fusion feature representation and the local attention fusion feature representation to obtain vertex vector representation. According to the invention, the association prediction accuracy of miRNA and physiological status types is improved.

The invention provides a pseudovirus of a Nipah virus and application of the pseudovirus, and belongs to the technical field of genetic engineering. The invention provides a pseudovirus of a Nipah virus and application of the pseudovirus. The pseudovirus contains a nucleic acid fragment of a Nipah virus N gene of which the nucleotide sequence is shown as SEQ ID NO.1. The invention further provides a preparation method of the pseudovirus. The pseudovirus of the Nipah virus can be used as a ribonucleic acid standard substance of the pseudovirus of the Nipah virus, and is applied to the aspects of quantity transmission, calibration, instrument testing, evaluation and control of a testing method, quality verification, quality control, production process detection and the like of a laboratory related to Nipah virus detection. The pseudovirus of the Nipah virus, as the ribonucleic acid standard substance of the pseudovirus of the Nipah virus, has the following advantages of accurate fixed value, good uniformity, stable quantity value and traceability, and can promote the improvement of the detection capability and the technical level of a national Nipah detection laboratory.

96 New PCT-Patent Application based on EP 24 186 635.9 Insempra GmbH Vossius Ref.: AG4141 PCT S3 Abstract The present invention relates to a linear double-stranded deoxyribonucleic acid (dsDNA) molecule comprising one or more Tus protein (Tus) binding site(s) at the 5'-terminus, one or more Lac repressor protein (LacI) binding site(s) at the 3'-terminus, and a segment comprising a DNA sequence of interest (DOI) between said Tus binding site(s) and said LacI binding site(s). The present invention further relates to a non-naturally or naturally occurring RNA molecule as encoded by or transcribable / transcribed from the linear dsDNA molecule of the invention, and to an expression DNA cassette comprising a promoter, an RBS, a GOI encoding a POI, and one or more LacI binding site(s), wherein said expression cassette does not comprise a terminator sequence between the 3´ end of said GOI and said one or more LacI binding site(s). The present invention also relates to a non-naturally or naturally occurring RNA molecule as encoded by or transcribable / transcribed from said expression cassette. The present invention further relates to method of protecting a linear deoxyribonucleic acid (DNA) molecule from exonuclease degradation by adding one or more Tus binding site(s) at the first terminus of the DNA molecule and adding one or more LacI binding site(s) at the other terminus of the DNA molecule. The present invention further relates to a method of synthesizing a protein of interest (POI) in a cell- free protein synthesis (CFPS) reaction mixture by using the (ds)DNA and / or RNA molecules of the invention, and also to a cell-free biological system or CFPS reaction mixture comprising the (ds)DNA, expression cassette and / or RNA molecules of the invention.

The invention provides double-stranded ribonucleic acid for reducing blood coagulation factor XI expression and a modifier and application of the double-stranded ribonucleic acid. Cell experiment results show that the oligonucleotide duplex can significantly inhibit the expression of the FXI gene, and can be used for developing anticoagulant drugs.

The invention discloses an extraction method and application of high-molecular-weight turbellarian worm genome DNA, and belongs to the field of turbellarian worm genome extraction.The turbellarian worm genome DNA extraction is achieved by improving a lysate formula and removing ethylenediaminetetraacetic acid and increasing Mg < 2 + > on the basis of a conventional reagent in a classic Tris-HCl-phenol-chloroform method to inhibit activity of deoxyribonuclease II in a turbellarian worm body to inhibit degradation of genome DNA, and the high-molecular-weight turbellarian worm genome DNA is obtained. Meanwhile, ribonuclease A is added, RNA in cells can be degraded in the tissue cell digestion process, so that the step of two times of purification is omitted, the loss of DNA yield is reduced, experimental steps are simplified, especially the step of DNA purification is reduced, the problem of degradation in the extraction process of the turbellarian turbellarian worm genome DNA is solved, and the genome DNA yield (gt; 10 micrograms per turbellarian worm), and the turbellarian worm genome ultra-long sequencing or PacBio high-fidelity sequencing requirements are met.

The invention relates to the technical field of medicines, and discloses a stress particle targeted degradation agent as well as a preparation method and application thereof. The compound provided by the invention comprises a ternary complex composed of a stress particle protein, a linking group and an E3 ubiquitin ligase ligand or a ternary complex composed of a stress particle protein, a linking group and a ribonuclease L ligand, the compounds connected with different ligands have good targeting and degradation effects on the stress particles, can be used as a stress particle targeting degradation agent to be applied to preparation of anti-tumor drugs and anti-neurodegenerative disease drugs, and have good application prospects in treatment of stress particle induced tumor drug resistance and neurodegenerative diseases.

A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

This application relates to a deoxyribonucleic acid and pseudovirus preservation solution, its preparation method and application. The deoxyribonucleic acid and pseudovirus preservation solution includes: a buffer solution with a final concentration of 5 mM to 50 mM, a surfactant with a volume percentage of 0.05% to 1.0%, trehalose with a final concentration of 50 mM to 500 mM, a metal ion chelator with a final concentration of 0.5 mM to 5 mM, betaine with a final concentration of 100 mM to 1000 mM, and mannitol with a mass percentage of 1% to 10%. Each specific component in the above-mentioned deoxyribonucleic acid and pseudovirus preservation solution cooperates with each other at a specific concentration, which has the effect of stabilizing the state and structure of nucleic acids. It can achieve the preservation of nucleic acids and pseudoviruses without ultra-low temperature, and can stably preserve nucleic acids and pseudoviruses for up to 12 months at 30°C without affecting subsequent detection tests.

The invention relates to pharmaceutical compositions comprising an iRNA agent, e.g., double stranded ribonucleic acid (dsRNA) agent and methods of using such compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without inhibitors).

The present disclosure provides siRNAs, modifiers, conjugates and uses thereof for targeted regulation of Factor 11 of coagulation (FXI) gene expression. A series of siRNAs are designed based on an FXI messenger ribonucleic acid (mRNA) sequence, alternate modification is carried out, and modification is carried out by utilizing a group of specific modification templates. Cellular and animal experiment results show that some alternately modified and specific template modified oligonucleotide sequences can significantly inhibit the expression of the FXI gene, and can be used for developing anticoagulant drugs.

The invention provides an invasive species identification method and device based on deep learning and DNA storage and electronic equipment, and relates to the technical field of invasive organism prevention and control, and the method comprises the steps: obtaining a to-be-identified invasive species image, and generating a first DNA sequence of a to-be-identified invasive species in the invasive species image through a deoxyribonucleic acid DNA encoder; obtaining a plurality of second DNA sequences to be hybridized from the invasive species database, and obtaining the hybridization yield of the first DNA sequence and each second DNA sequence by using a hybridization yield predictor; and determining the species category corresponding to the DNA sequence with the highest hybridization yield as the species category of the invasive species to be identified. According to the method provided by the invention, the strong feature extraction capability of deep learning is combined with the advantages of ultrahigh density and ultra-long stability of DNA as a data storage medium, so that end-to-end mapping and recognition from a species image to an exclusive DNA sequence thereof are realized.

The invention discloses an application of ribonuclease SiRe0902 with high efficiency and thermal stability in specific recognition of a GG site. The amino acid sequence of the gene is as shown in SEQ ID NO.2, and the nucleotide sequence of the gene is as shown in SEQ ID NO.1. The ribonuclease SiRe0902 has very efficient and specific RNA (Ribonucleic Acid) hydrolysis activity, and does not have non-specific cutting on DNA (Deoxyribose Nucleic Acid) at all. In addition, the enzyme is derived from thermophilic archaea, is detected to have good thermal stability, and has very good RNA cleavage activity under the conditions of 37 DEG C and 65 DEG C. Through detection, the enzyme can specifically recognize a GG sequence for cutting, and also has high cutting activity for the GG sequence in a secondary structural region. Therefore, the ribonuclease SiRe0902 is novel ribonuclease with thermal stability, has extremely high RNA hydrolytic activity under normal-temperature and high-temperature conditions, and meets the requirements in the fields of clinic, production, molecular cloning and the like.

The present disclosure provides a modified oligonucleotide sequence and its application. A series of siRNAs are designed based on the angiotensinogen (AGT) messenger ribonucleic acid (mRNA) sequence, and are alternately modified and modified using a specific set of modification templates. The results of cell and animal experiments show that some alternately modified and specifically template-modified oligonucleotide sequences can significantly inhibit the expression of the AGT gene, and can be used for developing drugs for treating related diseases such as hypertension.

The present disclosure provides methods of processing or analyzing a sample. A method for processing a sample may comprise hybridizing a probe molecule to a target region of a nucleic acid molecule (e.g., a ribonucleic acid (RNA) molecule), barcoding the probe-nucleic acid molecule complex, and performing extension, denaturation, and amplification processes. The nucleic acid molecule may be a nucleic acid molecule associated with CRISPR, (e.g., a guide RNA). A method for processing a sample may comprise hybridizing first and second probes to adjacent or non-adjacent target regions of a nucleic acid molecule (e.g., an RNA molecule such as a guide RNA molecule), linking the first and second probes to provide a probe-linked nucleic acid molecule, and barcoding the probe-linked nucleic acid molecule. One or more processes of the methods described herein may be performed within a partition, such as a droplet or well. One or more processes of the methods described herein may be performed on a cell, such as a permeabilized cell.

Provided herein are small interfering ribonucleic acid (siRNA) agents targeting a microtubule-associated protein tau (MAPT) gene and compositions comprising such siRNA agents.

Embodiments of the present disclosure relate to a composition that comprises a recombinant plasmid (RP) with a sequence of nucleic acids. The sequence comprise a start region, an end region and an insert positioned between the start region and the end region. The insert encodes for a sequence of micro interfering ribonucleic acid (miRNA) that may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint protein.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

The invention provides a preparation method of a pH-responsive release nucleic acid delivery system, and belongs to the technical field of nucleic acid delivery systems.The preparation method comprises the steps that 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride is used for enhancing the amino density of the surface of bovine serum albumin, modified bovine serum albumin and double-stranded ribonucleic acid are mixed according to the mass ratio of 10: 1, and a mixture is obtained; the preparation method comprises the following steps: adding glutaraldehyde as a cross-linking agent under the condition that the ratio of water to ethanol is 3: 1 to form Schiff base, reacting at 4 DEG C for 4-5 hours, and then performing ultrafiltration purification to obtain the double-stranded ribonucleic acid modified bovine serum albumin nanoparticles, thereby solving the technical problem of poor stability of double-stranded ribonucleic acid in noctuidae insects. And an efficient and accurate technical solution is provided for agricultural pest control.

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., Alzheimer's disease, atherosclerosis, or inflammation of the choroid plexus (ChP).

Several embodiments relate to methods of repairing and / or regenerating damaged or diseased tissue comprising administering to the damaged or diseased tissues compositions comprising exosomes. In several embodiments, the exosomes comprise one or more microRNA that result in alterations in gene or protein expression, which in turn result in improved cell or tissue viability and / or function.

Provided herein are nucleic acids useful as guide nucleic acids (gNAs), e.g., guide ribonucleic acids (gRNAs), in a CRISPR system wherein the guide nucleic acids contain one or more modifications to one or more nucleotides, use of such guide nucleic acids in modifying cells, and other uses wherein CRISPR Cas proteins are utilized.

The invention relates to methods of treating subjects that would benefit from reduction in expression of transthyretin (TTR), such as subjects having a TTR-associated disease, disorder, or condition, e.g., transthyretin-mediated amyloidosis, or Stargardt disease, using double-stranded ribonucleic acid (dsRNA) compositions targeting the TTR gene. The invention also provides methods for preventing at least one symptom in a subject having a TTR-associated disease, disorder, or condition, e.g., transthyretin-mediated amyloidosis, or Stargardt disease.

The present invention relates to methods for producing a protected deoxyribonucleic acid (DNA) product with enhanced resistance to nuclease digestion. The methods comprise digesting a double-stranded DNA molecule with an endonuclease to generate a digested double-stranded DNA molecule comprising a first strand and a second strand, wherein the first strand has a 5' overhang; and extending the second strand 5' to 3' using a polymerase in the presence of one or more nuclease-resistant deoxynucleotide triphosphates to generate the protected DNA product, wherein the protected DNA product comprises an extended second strand comprising at least one nuclease-resistant nucleotide incorporated into the extended second strand by the polymerase using the 5' overhang of the first strand as template. Also provided are protected DNA products and uses thereof.

Disclosed herein are double stranded ribonucleic acids (dsRNAs) and synthetic antisense oligonucleotides (ASOs) for use in inhibiting the expression of MUC5B and in the treatment of a subject having a disease or disorder characterized by overexpression of MUC5B, including in subjects having lung disease or in a subject at risk of developing lung disease, for example, in a subject having or at risk of developing idiopathic pulmonary fibrosis.